F ostered by refinements in device technology, improved imaging, and streamlining of the procedure, transcatheter aortic valve replacement (TAVR) plays an increasingly important role in the treatment of severe, symptomatic aortic stenosis.
for TAVR, the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) and the System for Cardiac Operative Risk Evaluation are routinely integrated in the heart team evaluation of patients with symptomatic severe aortic stenosis. However, both scores have been derived from cohorts of surgical patients; the extrapolation to patients with TAVR remains, therefore, challenging and their suitability arguable. 3, 4 In recent years, several attempts to develop TAVR-specific risk models have been performed. [5] [6] [7] [8] [9] [10] However, the majority of these novel scores have not been validated in external cohorts, limiting their adoption in clinical practice. Because prediction models are conceived to be applied to future patients, their value depends on the performance shown outside the development sample. To date, the Transcatheter Valve Therapy (TVT) registry model represents the score that has been derived from the largest cohort of patients with TAVR including 13 718 participants of the STS/American College of Cardiology TVT registry. 11 The aim of this study was to evaluate the extent of generalizability of the TVT registry model by quantifying its performance in an independent data set. For this purpose, we investigated its prediction accuracy in patients included in the prospective Swiss Transcatheter Aortic Valve Implantation (TAVI) registry.
Methods

Participants
The external validation cohort included all patients with severe native aortic valve stenosis who were consecutively treated and entered into the Swiss TAVI registry (NCT01368250) between February 2011 and February 2016. The details of the rationale and design of the Swiss TAVI registry have been described previously. 12 In brief, the Swiss TAVI registry is a nationwide registry that prospectively collects clinical and procedural data of patients undergoing TAVR with CE-marked devices in Switzerland with regular follow-up at 30 days, 1 year, and yearly thereafter. A dedicated clinical committee is responsible for the adjudication of the clinical events occurring during the index hospitalization or at follow-up according to the definitions of the Valve Academic Research Consortium-2 criteria. 13 The registry has been approved by the local ethics committee of all recruiting centers, and all patients provided written informed consent to participate.
Measurements
The TVT registry model was applied through the automatic calculator accessible online at http://tools.acc.org/TAVRRisk/. The model includes the following variables: (1) age at admission; (2) estimated glomerular filtration rate, calculated on the basis of age, sex, race, preprocedure creatinine, and requirement of preprocedure dialysis; (3) hemodialysis or peritoneal dialysis on an ongoing basis as a result of renal failure; (4) New York Heart Association functional class IV, defined as cardiac disease with dyspnea at rest that increases with any physical activity, resulting in inability to perform any physical activity without discomfort; (5) history of severe chronic lung disease, defined as forced expired volume in 1 second <50% predicted and room air p0 2 <60 or room air Pco 2 >50; (6) nonfemoral access site; (7) acuity status 2 defined as urgent procedure status plus no preprocedure shock, inotropes, mechanical assist device, or cardiac arrest; (8) acuity status 3 defined as elective or urgent procedure status plus preprocedure shock, inotropes, or mechanical assist device plus no prior cardiac arrest within 24 hours of procedure; (9) acuity status 4 defined as emergency or salvage procedure or prior cardiac arrest within 24 hours of operation. Definitions used in the Swiss TAVI and the TVT registry were similar with respect to the variables used in the model. Specifically, our registry records age at admission, dialysis status, New York Heart Association functional class, severe chronic lung disease, and femoral access. Glomerular filtration rate was calculated according to the modification of diet in renal disease equation and presence of dialysis. Because acuity categories are not included in the Swiss TAVI registry variables, we derived acuity status (2, 3, or 4) by matching the setting of the procedure (elective or urgent) and hemodynamic status (cardiogenic shock).
The present study complies with the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis guidelines for the reporting of studies that validate prediction scores (Table I in the Data Supplement).
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Statistical Analysis
Patient baseline characteristics were expressed as means and SD or frequencies (percentage). Validation of the TVT registry model was performed by examining measures of discrimination and calibration. Discrimination describes the power of models to distinguish patients who have events (death) from those who have no events. It was assessed using the C index that represents the area under the receiver operating characteristic curve and for which larger values are associates with better discrimination. Calibration is a measure of how closely the predicted probabilities (of death) reflect the actual risk; it was assessed by performing the Hosmer-Lemeshow goodness-of-fit test and was graphically depicted in the plot of observed versus predicted mortality with a value <0.05 indicating significant difference in expected versus observed mortality. Calibration was also assessed by testing for an intercept of zero and a slope of 1 when regressing observed proportion of deaths on predicted proportion of deaths based on the TVT. Deciles of the TVT score were used to calculate proportions. Although acknowledging that the TVT registry model was designed to predict in-hospital mortality, we additionally tested whether it could be predictive of mortality at 30 days after TAVR. Model performance in terms of calibration was also examined in prespecified subgroups defined by age of <85 years or older, estimated
WHAT IS KNOWN
• Prediction models may improve the management of patients with severe aortic valve stenosis undergoing transcatheter aortic valve replacement.
• Risk scoring systems derived from surgical cohorts proved suboptimal performance when applied to transcatheter aortic valve replacement populations.
• The Transcatheter Valve Therapy registry model has been derived to predict in-hospital mortality after transcatheter aortic valve replacement with modest discrimination and good calibration in the development cohort.
WHAT THE STUDY ADDS
• The predictive performance of the Transcatheter Valve Therapy registry model is preserved in an independent, non-US cohort of patients with transcatheter aortic valve replacement.
• The predictive accuracy is maintained ≤30 days after the procedure.
• In a comparative analysis with the Society of Thoracic Surgeons Predicted Risk of Mortality score, the Transcatheter Valve Therapy registry model showed better calibration for prediction of inhospital and 30-day mortality. glomerular filtration rate <60 mL/min, between 60 and 90 mL/min, or >90 mL/min, need for dialysis, New York Heart Association class IV or class I to III, nonfemoral access, acuity categories, and sex. The main analyses were repeated after multiple imputation of missing variables. In addition, we examined the predictive accuracy of the STS-PROM score and compared it with that of the TVT registry model using the DeLong method. The STS-PROM score was calculated at the time of intervention according to the models developed from the STS database, available at http://riskcalc.sts.org/stswebriskcalc/.
Analyses were conducted using Stata Statistical Software, Release 14.1 (StataCorp LP, College Station, TX), and statistical significance was defined as P<0.05.
Results
The validation cohort comprised 3491 consecutive patients included into the Swiss TAVI registry between February 2011 and February 2016. In-hospital and thirty-day survival data were available for the entire cohort. Rates of in-hospital and 30-day mortality amounted to 2.9% and 3.8%, respectively. Table 1 summarizes the baseline clinical characteristics of patients who died in hospital versus those who survived. Male and female patients were similarly represented in either group. Mean STS-PROM score was 5.8±4.5, and it was significantly higher in patients who died in hospital (7.6±5.9 versus 5.8±4.4; P<0.001). Nonsurvivors were older compared with survivors (84.2±5.7 versus 82.1±6.5 years; P=0.001) and more often presented with renal dysfunction. In addition, nonsurvivors more commonly presented with cardiogenic shock (5% versus 1%; P<0.001) and more often underwent urgent instead of elective TAVI (acuity category 2 or 4). Type of transcatheter heart valves used are reported in Table II 
Performance of the TVT Registry Model
The performance of the TVT registry model in the Swiss TAVI cohort was assessed using the original coefficients that were obtained in the development sample. Refitted model coefficients and odds ratios with 95% confidence interval (CI) for each covariate in the validation cohort are reported for descriptive purposes in Table IV in the Data Supplement. In the Swiss TAVI registry cohort, the TVT registry model showed moderate discrimination, with a C index for in-hospital mortality of 0.66 and 95% CI, 0.60 to 0.72 ( Figure 1A) . Moreover, the C index for prediction of 30-day mortality was 0.67 and 95% CI, 0.65 to 0.69 ( Figure 1C ). The results were consistent when analyzing the performance of the model among patients included in the Swiss TAVI registry during the same period of patients included in the derivation cohort (Table V in the Data  Supplement) .
Calibration plots are shown in Figure 2A and 2C. A close agreement between predicted versus observed mortality was documented for both in-hospital and 30-day outcome. Model calibration was preserved across several prespecified subgroups; we recorded, however, an overestimation of inhospital and 30-day mortality for patients on hemodialysis (Figure 3) .
Performance of the STS-PROM Score
As shown in Figure 1B and 1D, the STS-PROM score achieved moderate discriminative ability for prediction of in-hospital 
Discussion
The main findings of our study validating the performance of the TVT registry model in a large cohort of patients undergoing TAVR at multiple centers in Switzerland can be summarized as follows: (1) the TVT registry model showed moderate discrimination and adequate calibration for the prediction of in-hospital mortality after TAVR, (2) its predictive accuracy was maintained for mortality at 30 days, and (3) the TVT registry model showed significantly better predictive accuracy in terms of calibration as compared with the STS-PROM score, whereas discrimination was comparable.
The TVT registry model has been recently developed to predict in-hospital mortality in a cohort of >13 000 patients undergoing TAVR in the United States between 2011 and 2014. The internal validation cohort comprised >6000 patients treated between March and October 2014. The model showed moderate discrimination with a C index of 0.67 (95% CI, 0.65-0.69) in the development group and 0.66 (95% CI, 0.62-0.69) in the validation group, respectively, and good calibration. Although alternative scores have been both derived and validated in relatively small cohorts, the TVT registry model has been derived and validated in a cohort surpassing the The time interval of patients included in the present analysis largely corresponded with the time interval of the STS/ American College of Cardiology TVT registry. In our study, we found a discrimination of the TVT registry model for the prediction of in-hospital mortality comparable with the original report; moreover, discrimination was maintained at 30 days after the procedure. This clearly defined time window allows for a better assessment of early outcomes after TAVR because in-hospital length of stay may be highly variable across different centers.
A risk-benefit analysis is an integral part of the Heart Team assessment for the selection of the optimal treatment strategy for patients with severe aortic valve stenosis. Clinical and anatomic characteristics complement the multidisciplinary evaluation of the patient and are consolidated in specific scores quantifying periprocedural risk. Risk scores allow for the possibility of comparing health across different populations. Several risk scores have proven instrumental for surgical procedures and are regularly harmonized with updated information on contemporary event rates. In the absence of a tailored risk score for TAVR, risk models originally derived from surgical cohorts have been used for the definition of risk categories and patient selection in randomized trials of TAVR versus surgical aortic valve replacement. [15] [16] [17] However, there is a large body of evidence demonstrating a suboptimal performance of such scores in TAVR cohorts. Indeed, in the PARTNER I trial (Placement of Aortic Transcatheter Valves) and continued access registry, both the STS-PROM score and the Logistic System for Cardiac Operative Risk Evaluation overestimated the mortality occurring in-hospital or at 30 days after TAVR. 3 Along the same line, in a retrospective analysis of patients treated with the Medtronic CoreValve prosthesis at 2 European centers, both the Logistic System for Cardiac Operative Risk Evaluation and the STS-PROM algorithm were found to have suboptimal discriminatory power and calibration. 4 Consistently, in our cohort, the STS-PROM score showed poorer calibration among patients with higher estimated mortality risk. This finding does not only pertain to the field of TAVR but has already been reported in surgical series. 18 Arguably, such suboptimal calibration in high-risk categories may stem from high mortality rates in the original derivation cohort of the STS-PROM score. 
observed=calibration). Observed mortality is represented with 95% confidence intervals (error bars). External Validation of the TVT Registry Model
More recently, several TAVR-specific risk scores have been suggested, as summarized in Table 4 . Most scores have been validated for 30-day mortality and were found to have a C index ranging from 0.57 to 0.75. Although applicability of both the STS-PROM score and the System for Cardiac Operative Risk Evaluation has been repeatedly questioned in view of their derivation and validation in patients with surgical access, the TVT risk model is the first among the specific TAVR risk scores to differentiate between transfemoral and alternative (surgical) approach for TAVR.
Currently available risk scores for TAVR are limited by several factors. Time is an important covariable rarely accounted for in conventional risk scores. A discount in risk over time has been observed for the STS-PROM score resulting in a reclassification of more than half of patients originally deemed to be high risk to intermediate risk in an analysis repeated 6 to 7 years after the first analysis. 19 Sensitive scores work bidirectionally: they inform about anticipated risk, while regularly being updated by the most recent outcome data. This may be particularly important in a rapidly evolving field, such as TAVR, where device iterations have been shown to substantially reduce periprocedural complications as reflected by a large heterogeneity of reported outcomes across major studies. Moreover, deficiencies of standard modelling methods, relatively small and homogenous derivation cohorts, and absence of validation in external datasets further hamper the robustness of existing TAVR risk scores. To date, there were no studies assessing the reproducibility and transportability of the TVT registry model. Geographical variability in performance is mainly related to variation in case mix, that is dissimilarity between patients in different countries. 20 In our study, the predictive accuracy of the TVT registry model was confirmed in an unselected cohort of consecutive patients treated in Switzerland. The reproducibility of the results observed in the development cohort is an important finding in view of the expected differences between the 2 sides of the Atlantic in terms of patient features, devices, procedural characteristics, and postprocedural care. Some concerns may arise about model performance because its discrimination was 
Limitations
We acknowledge the following limitations of our study: (1) although we were able to include a large contemporary TAVR population with excellent documentation of baseline and follow-up status, the TVT registry model was validated in a retrospective manner; (2) we were unable to assess the added value of indices of frailty and measures of quality of life that were not included in the original model because they are not systematically collected in our database; (3) the results of our validation analysis may be affected by the impossibility to quantify the case-mix differences between development and validation samples because, with the exception of age and sex, no other baseline clinical characteristics of the original cohort were available; (4) although predicted versus observed mortality was consistent for both in-hospital and 30-day outcomes across several subgroups, an overestimation of inhospital and 30-day mortality for patients on hemodialysis was observed. This should be carefully interpreted in view of multiple testing and the small number of patients included in this subgroup; (5) we were unable to assess the comparative performance of the TVT registry model and other risk scores because measures such as frailty, mini-mental status examination, 6-minute walk test distance, assisted living, home oxygen use, and Charlson Comorbidity Index are not systematically collected in our database; (6) in view of the ongoing expansion of TAVR adoption in lower-risk patients, further studies are needed to validate the accuracy of this model in low-risk populations.
Conclusions
In a large, multicenter, non-US cohort of patients with TAVR, the validation of the TVT registry model demonstrated moderate discrimination and good calibration for the prediction of in-hospital and 30-day mortality. As a result, the TVT registry model should be considered an alternative to the STS-PROM score for decision making and assessment of early outcome in patients eligible for TAVR.
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